<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Baker Brothers Life Sciences LP -->
          <cik>0001363364</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001359931</issuerCik>
      <issuerName>Protara Therapeutics, Inc.</issuerName>
      <secFileNumber>001-36694</secFileNumber>
      <issuerAddress>
        <com:street1>345 Park Avenue South</com:street1>
        <com:street2>Third Floor</com:street2>
        <com:city>New York</com:city>
        <com:stateOrCountry>NY</com:stateOrCountry>
        <com:zipCode>10010</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>646-844-0337</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Baker Brothers Life Sciences, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Former Affiliate</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Canaccord Genuity LLC</name>
        <address>
          <com:street1>99 High Street,</com:street1>
          <com:street2>Suite 1200</com:street2>
          <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02110</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>322039</noOfUnitsSold>
      <aggregateMarketValue>1944922.00</aggregateMarketValue>
      <noOfUnitsOutstanding>53587260</noOfUnitsOutstanding>
      <approxSaleDate>02/24/2026</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>12/08/2025</acquiredDate>
      <natureOfAcquisitionTransaction>See Remark 2</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Underwriter</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>322039</amountOfSecuritiesAcquired>
      <paymentDate>12/08/2025</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>(1) Baker Brothers Life Sciences, L.P. is affiliated with 667, L.P. Baker Bros. Advisors LP is the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. 667, L.P. is filing separately for the sale of 26,755 shares of common stock ("Common Stock") of Protara Therapeutics, Inc. (the "Issuer"), which along with the reported sales in this form by Baker Brothers Life Sciences, L.P. totals 348,794 shares of Common Stock. (2) Common Stock acquired in underwritten public offering.</remarks>
    <noticeSignature>
      <noticeDate>02/24/2026</noticeDate>
      <signature>By: BAKER BROS. ADVISORS LP, mgmt company and IA to Baker Brothers Life Sciences, L.P., /s/ Scott L. Lessing, President</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
